Skip to main
CANF

CANF Stock Forecast & Price Target

CANF Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Can Fite Biopharma's positive outlook is bolstered by its strong pipeline of drug candidates, with risk-adjusted sales projections for Namodenoson and Piclidenoson showing substantial growth, from approximately $3 million in 2027 to $126 million by 2031. The company is positioning its drugs for initial market entry at the end of 2027, with a projected peak market penetration of 5%, indicating optimism around potential market acceptance and competitive positioning. Additionally, compelling clinical results, including a significant complete response in a patient with advanced liver cancer treated with Namodenoson, enhance the prospects for securing FDA and EMA approvals, affirming the potential for successful commercialization of its therapies.

Bears say

Can Fite Biopharma Ltd is facing significant challenges that contribute to a negative outlook on its stock. The company's inability to successfully commercialize its drug products or achieve the expected market penetration could severely impact revenue forecasts, while potential delays in regulatory approvals may hinder its financial performance further. Additionally, the projection of increasing net losses, along with anticipated dilution and heightened competitive pressures, raises concerns about the company's future viability and its ability to protect intellectual property rights.

CANF has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Can-Fite BioPharma Ltd. (CANF) Forecast

Analysts have given CANF a Strong Buy based on their latest research and market trends.

According to 2 analysts, CANF has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Can-Fite BioPharma Ltd. (CANF)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.